Literature DB >> 8628733

Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.

K C Chou1, A G Tomasselli, I M Reardon, R L Heinrikson.   

Abstract

Based on the sequence-coupled (Markov chain) model and vector-projection principle, a discriminant function method is proposed to predict sites in protein substrates that should be susceptible to cleavage by the HIV-1 protease. The discriminant function is defined by delta = phi+ - phi-, where phi+ and phi- are the cleavable and noncleavable attributes for a given peptide, and they can be derived from two complementary sets of peptides, S+ and S-, known to be cleavable and noncleavable, respectively, by the enzyme. The rate of correct prediction by the method for the 62 cleavable peptides and 239 noncleavable peptides in the training set are 100 and 96.7%, respectively. Application of the method to the 55 sequences which are outside the training set and known to be cleaved by the HIV-1 protease accurately predicted 100% of the peptides as substrates of the enzyme. The method also predicted all but one of the sites hydrolyzed by the protease in native HIV-1 and HIV-2 reverse transcriptases, where the HIV-1 protease discriminates between nearly identical sequences in a very subtle fashion. Finally, the algorithm predicts correctly all of the HIV-1 protease processing sites in the native gag and gag/pol HIV-1 polyproteins, and all of the cleavage sites identified in denatured protease and reverse transcriptase. The new predictive algorithm provides a novel route toward understanding the specificity of this important therapeutic target.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628733     DOI: 10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  25 in total

1.  Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease.

Authors:  C D Rosin; R K Belew; G M Morris; A J Olson; D S Goodsell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

2.  Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease.

Authors:  Ayşegül Özen; Kuan-Hung Lin; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-29       Impact factor: 11.205

3.  Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.

Authors:  Jennifer E Foulkes; Moses Prabu-Jeyabalan; Deyna Cooper; Gavin J Henderson; Janera Harris; Ronald Swanstrom; Celia A Schiffer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells.

Authors:  R L Shoeman; C Hüttermann; R Hartig; P Traub
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

5.  PROSPERous: high-throughput prediction of substrate cleavage sites for 90 proteases with improved accuracy.

Authors:  Jiangning Song; Fuyi Li; André Leier; Tatiana T Marquez-Lago; Tatsuya Akutsu; Gholamreza Haffari; Kuo-Chen Chou; Geoffrey I Webb; Robert N Pike; John Hancock
Journal:  Bioinformatics       Date:  2018-02-15       Impact factor: 6.937

6.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 7.  Some illuminating remarks on molecular genetics and genomics as well as drug development.

Authors:  Kuo-Chen Chou
Journal:  Mol Genet Genomics       Date:  2020-01-01       Impact factor: 3.291

8.  Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.

Authors:  John M Louis; József Tözsér; Julien Roche; Krisztina Matúz; Annie Aniana; Jane M Sayer
Journal:  Biochemistry       Date:  2013-10-15       Impact factor: 3.162

9.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.

Authors:  Linda L Dunn; Mary Jane McWilliams; Kalyan Das; Eddy Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.